CA3076202A1 - Cyclic iminopyrimidine derivatives as kinase inhibitors - Google Patents
Cyclic iminopyrimidine derivatives as kinase inhibitors Download PDFInfo
- Publication number
- CA3076202A1 CA3076202A1 CA3076202A CA3076202A CA3076202A1 CA 3076202 A1 CA3076202 A1 CA 3076202A1 CA 3076202 A CA3076202 A CA 3076202A CA 3076202 A CA3076202 A CA 3076202A CA 3076202 A1 CA3076202 A1 CA 3076202A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- quinazolin
- oxy
- mmol
- sulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561142P | 2017-09-20 | 2017-09-20 | |
| US62/561,142 | 2017-09-20 | ||
| PCT/US2018/052047 WO2019060611A1 (en) | 2017-09-20 | 2018-09-20 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3076202A1 true CA3076202A1 (en) | 2019-03-28 |
Family
ID=64457074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076202A Pending CA3076202A1 (en) | 2017-09-20 | 2018-09-20 | Cyclic iminopyrimidine derivatives as kinase inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11254680B2 (https=) |
| EP (1) | EP3684772B1 (https=) |
| JP (1) | JP7394768B2 (https=) |
| KR (1) | KR102796209B1 (https=) |
| CN (1) | CN111247152B (https=) |
| AU (1) | AU2018338098B2 (https=) |
| CA (1) | CA3076202A1 (https=) |
| MX (1) | MX2020003126A (https=) |
| WO (1) | WO2019060611A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| KR20230112605A (ko) * | 2020-08-07 | 2023-07-27 | 에이비엠 쎄라퓨틱스 코포레이션 | 키나아제 억제제 및 그의 용도 |
| CN114380697A (zh) * | 2021-11-30 | 2022-04-22 | 上海毕得医药科技股份有限公司 | 一种n-甲基乙基胺盐酸盐的制备工艺 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN117209503B (zh) * | 2023-09-13 | 2025-10-17 | 苏州翔实医药发展有限公司 | 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| TW202545530A (zh) * | 2024-01-17 | 2025-12-01 | 大陸商海思科醫藥集團股份有限公司 | 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用 |
| WO2025176185A1 (zh) * | 2024-02-23 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种braf抑制剂的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE411996T1 (de) * | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| CN101932580B (zh) | 2007-06-01 | 2013-05-22 | 葛兰素史密丝克莱恩有限责任公司 | 咪唑并吡啶激酶抑制剂 |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| CN103339132B (zh) | 2010-12-02 | 2017-02-15 | 株式会社麦迪帕克特 | 嘌呤基吡啶基氨基‑2,4‑二氟苯基磺酰胺衍生物、其药学上可接受的盐、其制备方法及包含其作为活性成分的对Raf激酶具有抑制活性的药物组合物 |
| US20130023531A1 (en) * | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| RU2015113597A (ru) * | 2012-09-14 | 2016-11-10 | Итернити Байосайенс Инк. | Производные аминоизохинолина в качестве ингибиторов протеинкиназы |
| US9688635B2 (en) * | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9321762B2 (en) * | 2013-12-11 | 2016-04-26 | Development Center For Biotechnology | Quinazoline compounds, method for preparing the same and use thereof |
| CN105272970A (zh) * | 2014-07-03 | 2016-01-27 | 中国药科大学 | 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途 |
| CA2954879C (en) | 2014-07-16 | 2022-09-06 | Development Center For Biotechnology | Quinoxaline compounds, method for preparing the same and use thereof |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
-
2018
- 2018-09-20 EP EP18808139.2A patent/EP3684772B1/en active Active
- 2018-09-20 MX MX2020003126A patent/MX2020003126A/es unknown
- 2018-09-20 KR KR1020207010704A patent/KR102796209B1/ko active Active
- 2018-09-20 CA CA3076202A patent/CA3076202A1/en active Pending
- 2018-09-20 CN CN201880067947.0A patent/CN111247152B/zh active Active
- 2018-09-20 AU AU2018338098A patent/AU2018338098B2/en active Active
- 2018-09-20 US US16/648,908 patent/US11254680B2/en active Active
- 2018-09-20 JP JP2020538750A patent/JP7394768B2/ja active Active
- 2018-09-20 WO PCT/US2018/052047 patent/WO2019060611A1/en not_active Ceased
-
2022
- 2022-01-13 US US17/575,292 patent/US11932647B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3684772A1 (en) | 2020-07-29 |
| CN111247152A (zh) | 2020-06-05 |
| MX2020003126A (es) | 2020-10-01 |
| JP2020534373A (ja) | 2020-11-26 |
| US11932647B2 (en) | 2024-03-19 |
| RU2020113707A3 (https=) | 2021-12-23 |
| CN111247152B (zh) | 2024-07-16 |
| JP7394768B2 (ja) | 2023-12-08 |
| KR102796209B1 (ko) | 2025-04-16 |
| US20200247813A1 (en) | 2020-08-06 |
| RU2020113707A (ru) | 2021-10-20 |
| AU2018338098A1 (en) | 2020-05-07 |
| BR112020005455A2 (pt) | 2020-09-24 |
| US20220251089A1 (en) | 2022-08-11 |
| KR20200055034A (ko) | 2020-05-20 |
| EP3684772B1 (en) | 2023-12-06 |
| EP3684772C0 (en) | 2023-12-06 |
| US11254680B2 (en) | 2022-02-22 |
| WO2019060611A1 (en) | 2019-03-28 |
| AU2018338098B2 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932647B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| CA3047106A1 (en) | Aminothiazole compounds as c-kit inhibitors | |
| US20210145771A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| CA2916419C (en) | Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
| AU2014312245A1 (en) | Heterocyclic compounds and methods of use | |
| JP2016513685A (ja) | クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 | |
| WO2017083756A1 (en) | Heterocyclic compounds for the treatment of disease | |
| CA3179325A1 (en) | Kinase inhibitors and uses thereof | |
| WO2018211324A1 (en) | Prodrugs for the treatment of disease | |
| TW202434590A (zh) | 稠合雙環化合物 | |
| RU2801302C2 (ru) | Производные циклического иминопиримидина в качестве ингибиторов киназ | |
| TW202229251A (zh) | 乙醯胺基－苯基苯甲醯胺衍生物及其使用方法 | |
| BR112020005455B1 (pt) | Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula | |
| BR112019025158A2 (pt) | Derivados de ácido carboxílico como inibidores das proteínas quinase | |
| CN110724076B (zh) | 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途 | |
| HK40031627A (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| HK40031627B (zh) | 作为激酶抑制剂的环状亚氨基嘧啶衍生物 | |
| WO2025247067A1 (zh) | Kif18A抑制剂 | |
| US9321766B1 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240917 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240917 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250704 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250704 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250812 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260114 |